Drug · CHEMBL1336

SORAFENIB

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. SORAFENIB. Drugs and targets, record CHEMBL1336. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1336

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: SORAFENIB; ChEMBL
ChEMBL ID: CHEMBL1336; ChEMBL
Type: Small molecule; ChEMBL
Other names: BAY 43-9006, BAY-43-9006; ChEMBL
Other form: CM-4307, CHEMBL4297490; Drugs and targets
Other form: SORAFENIB TOSYLATE, CHEMBL1200485; Drugs and targets
DrugBank: DB00398; DrugBank
InChIKey: MLDQJTXFUGDVEO-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 3 of its 131 diseases, from ATC, EMA Human Drugs and TTD; Open Targets

Targets9

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
BRAF	Serine/threonine-protein kinase B-raf	Serine/threonine-protein kinase B-raf inhibitor	INHIBITOR	https://conductscience.org/library/genes/673
FLT1	Vascular endothelial growth factor receptor	Vascular endothelial growth factor receptor inhibitor	INHIBITOR	https://conductscience.org/library/genes/2321
FLT3	Receptor-type tyrosine-protein kinase FLT3	Tyrosine-protein kinase receptor FLT3 inhibitor	INHIBITOR	https://conductscience.org/library/genes/2322
FLT4	Vascular endothelial growth factor receptor	Vascular endothelial growth factor receptor inhibitor	INHIBITOR	https://conductscience.org/library/genes/2324
KDR	Vascular endothelial growth factor receptor	Vascular endothelial growth factor receptor inhibitor	INHIBITOR	https://conductscience.org/library/genes/3791
KIT	Mast/stem cell growth factor receptor Kit	Stem cell growth factor receptor inhibitor	INHIBITOR	https://conductscience.org/library/genes/3815
PDGFRB	Platelet-derived growth factor receptor beta	Platelet-derived growth factor receptor beta inhibitor	INHIBITOR	https://conductscience.org/library/genes/5159
RAF1	RAF proto-oncogene serine/threonine-protein kinase	Serine/threonine-protein kinase RAF inhibitor	INHIBITOR	https://conductscience.org/library/genes/5894
RET	Proto-oncogene tyrosine-protein kinase receptor Ret	Tyrosine-protein kinase receptor RET inhibitor	INHIBITOR	https://conductscience.org/library/genes/5979

Source ChEMBL

Diseases131

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
hepatocellular carcinoma	Approval	EMA Human Drugs	211	208	https://conductscience.org/library/drugs?q=MONDO_0007256
renal cell carcinoma	Approval	EMA Human Drugs and TTD	71	68	https://conductscience.org/library/drugs?q=MONDO_0005086
acute myeloid leukemia	Phase 3	ClinicalTrials.gov	37	37	https://conductscience.org/library/drugs?q=MONDO_0018874
non-small cell lung carcinoma	Phase 3	ClinicalTrials.gov	28	28	https://conductscience.org/library/drugs?q=MONDO_0005233
breast cancer	Phase 3	ClinicalTrials.gov	24	24	https://conductscience.org/library/drugs?q=MONDO_0007254
melanoma	Phase 3	ClinicalTrials.gov	20	20	https://conductscience.org/library/drugs?q=MONDO_0005105
colorectal cancer	Phase 2	ClinicalTrials.gov	13	13	https://conductscience.org/library/drugs?q=MONDO_0005575
myelodysplastic syndrome	Phase 2/3	ClinicalTrials.gov	12	11	https://conductscience.org/library/drugs?q=MONDO_0018881
prostate cancer	Phase 2	ClinicalTrials.gov	10	10	https://conductscience.org/library/drugs?q=MONDO_0008315
malignant pancreatic neoplasm	Phase 2	ClinicalTrials.gov	9	9	https://conductscience.org/library/drugs?q=MONDO_0009831

1 to 10 of 131Source Open Targets

See all 131 diseases

Trials621

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00326898	Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery	Phase 3	1,943	2016-12-12	sorafenib	Its name	ClinicalTrials.gov
NCT01371981	Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	Phase 3	1,645	2020-07-07	sorafenib	Its name	ClinicalTrials.gov
NCT00692770	Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)	Phase 3	1,114	2014-12-01	sorafenib	Its name	ClinicalTrials.gov
NCT00699374	Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer	Phase 3	1,075	2013-01-14	sorafenib	Its name	ClinicalTrials.gov
NCT01761266	A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma	Phase 3	954	2018-09-25	sorafenib	Its name	ClinicalTrials.gov
NCT00300885	A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)	Phase 3	926	2010-09-20	sorafenib	Its name	ClinicalTrials.gov
NCT00449033	A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)	Phase 3	904	2011-09-09	sorafenib	Its name	ClinicalTrials.gov
NCT00073307	Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer	Phase 3	903	2011-12-14	sorafenib	Its name	ClinicalTrials.gov
NCT00110019	Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery	Phase 3	823	2012-09-27	sorafenib	Its name	ClinicalTrials.gov
NCT02576509	An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma	Phase 3	743	2020-06-26	sorafenib	Its name	ClinicalTrials.gov

1 to 10 of 621

See all 621 trials

Comparisons in its trials100

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Sorafenib (Nexavar, BAY43-9006) vs Placebo: serious adverse events	228 of 559	230 of 548	1,107	NCT00692770	Trial comparisons
Sunitinib vs Sorafenib: serious adverse events	240 of 526	204 of 542	1,068	NCT00699374	Trial comparisons
Lenvatinib vs Sorafenib: deaths from any cause	415 of 478	402 of 476	954	NCT01761266	Trial comparisons
Lenvatinib vs Sorafenib: serious adverse events	209 of 476	149 of 475	951	NCT01761266	Trial comparisons
Sorafenib + C/P vs Placebo + C/P: serious adverse events	272 of 463	195 of 459	922	NCT00300885	Trial comparisons
Sorafenib (Nexavar, BAY43-9006) + GC vs Placebo + GC: serious adverse events	270 of 452	198 of 449	901	NCT00449033	Trial comparisons
Arm I (Carboplatin + Paclitaxel + Sorafenib) vs Arm II (Carboplatin + Paclitaxel+Placebo): serious adverse events	332 of 393	311 of 397	790	NCT00110019	Trial comparisons
Nivolumab 240 mg vs Sorafenib 400 mg: deaths from any cause	321 of 371	335 of 372	743	NCT02576509	Trial comparisons
Nivolumab 240 mg vs Sorafenib 400 mg: serious adverse events	216 of 367	216 of 363	730	NCT02576509	Trial comparisons
Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva) vs Sorafenib (Nexavar, BAY 43-9006) + Placebo: Tumor Response	24 of 362	14 of 358	720	NCT00901901	Trial comparisons

1 to 10 of 100

See all 100 comparisons in its trials

Papers from its trials359

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39435268	RESULT	1	PubMed
38610840	RESULT	1	PubMed
37796513	RESULT	1	PubMed
37774329	RESULT	1	PubMed
36970591	RESULT	1	PubMed
36891979	RESULT	1	PubMed
36753026	RESULT	1	PubMed
36742297	RESULT	1	PubMed
36569829	RESULT	1	PubMed
36389129	RESULT	1	PubMed

1 to 10 of 359

See all 359 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL1336

GET https://conductscience.org/api/drugs/v1/CHEMBL1336/diseases?page=2

API reference For AI assistants